Novo Nordisk A/S (NYSE:NVO) Given Average Recommendation of "Hold" by Brokerages

Key Points

• Analyst consensus: Hold — 21 analysts give Novo Nordisk an average rating of "Hold" (2 sell, 12 hold, 6 buy, 1 strong buy) with an average 12‑month price target of $56.83.
• Analyst views are mixed and shifting: Morgan Stanley downgraded to underweight and cut its target to $47, Goldman lowered its target to $54 but kept a buy, while Sanford Bernstein upgraded to outperform and HSBC moved from strong‑buy to hold.
• Recent results and market position: shares trade around $49.35 with a $220.3B market cap and P/E of 13.6; the company beat EPS estimates ($1.02 vs. $0.77) but missed revenue slightly, and the stock sits well below its 52‑week high of $112.52.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) has been assigned an average rating of "Hold" from the twenty-one analysts that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $56.8333.

NVO has been the topic of several recent research reports. Weiss Ratings upgraded Novo Nordisk A/S from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Monday. The Goldman Sachs Group decreased their price objective on Novo Nordisk A/S from $60.00 to $54.00 and set a "buy" rating on the stock in a research note on Friday. Morgan Stanley downgraded Novo Nordisk A/S from an "overweight" rating to an "underweight" rating and cut their target price for the stock from $59.00 to $47.00 in a research note on Monday, September 29th. Hsbc Global Res lowered Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Monday, November 24th. Finally, Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday, September 9th.

Institutional Investors Weigh In On Novo Nordisk A/S

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Revolve Wealth Partners LLC increased its holdings in shares of Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock worth $214,000 after buying an additional 200 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Novo Nordisk A/S during the first quarter valued at about $41,000. GSA Capital Partners LLP purchased a new stake in Novo Nordisk A/S in the 1st quarter worth approximately $923,000. Banque Cantonale Vaudoise purchased a new stake in Novo Nordisk A/S in the first quarter worth $1,013,000. Finally, XTX Topco Ltd bought a new stake in Novo Nordisk A/S in the first quarter valued at $706,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Trading Up 1.3%

Shares of Novo Nordisk A/S stock opened at $49.35 on Friday. The stock has a market capitalization of $220.33 billion, a P/E ratio of 13.56, a P/E/G ratio of 2.33 and a beta of 0.65. Novo Nordisk A/S has a 52-week low of $43.08 and a 52-week high of $112.52. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. The stock's 50-day simple moving average is $52.81 and its 200 day simple moving average is $59.73.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.25. The firm had revenue of $11.79 billion during the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. Novo Nordisk A/S has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.